Status and phase
Conditions
Treatments
About
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:
SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
90 participants in 3 patient groups
Loading...
Central trial contact
Yukio Nakamura
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal